Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.
Core Innovation
The invention relates to isolated short peptides comprising up to 10 amino acids, defined by proline-rich sequence formulas including SEQ ID NOs: 1, 3, 4, 5, 6, 17 and 18. The peptides are stated to reduce dexamethasone-induced spleen and/or thymus weight loss in mice, and specific proline-containing substitutions and related peptide sequence definitions yield peptides with in vivo activity.
The disclosure addresses dexamethasone-induced spleen and thymus weight loss in a mouse as a measure of injury and/or stress-related effects following dexamethasone treatment. It provides isolated peptides capable of reducing such weight loss and discusses mechanistic rationale in terms of proline cis and trans conformational effects.
The disclosure identifies the base peptide LPPLPYP (SEQ ID NO: 2; Stressin-1/ IPL344) and states that specific substitutions in the base peptide yield peptides such as SEQ ID NO: 4 with significant in vivo activity. It also discusses stress and apoptosis-related pathways, including apoptosis, p53, cytokine secretion such as TNF-α and IL-6, and effects in macrophages.
Claims Coverage
The provided independent claim covers one isolated peptide defined by a specific sequence identity (SEQ ID NO: 21) with a D-amino acid at position 1, and the peptide is capable of reducing dexamethasone-induced spleen and/or thymus weight loss in a mouse. The dependent claim adds a pharmaceutical composition comprising the peptide.
Isolated peptide of SEQ ID NO: 21 with D-amino acid at position 1
An isolated peptide consisting of the amino acid sequence set forth in SEQ ID NO: 21, wherein the amino acid at position 1 is a D-amino acid.
Reduction of dexamethasone-induced spleen and/or thymus weight loss in a mouse
The peptide is capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse.
Pharmaceutical composition comprising the peptide
A pharmaceutical composition comprising the isolated peptide of claim 1.
Across the claim scope, the core inventive limitations are the identity of the isolated peptide sequence, the D-amino acid at position 1, and the functional capability to reduce dexamethasone-induced spleen and/or thymus weight loss in a mouse. The dependent claim further limits coverage to pharmaceutical compositions containing the claimed peptide.
Stated Advantages
Reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse.
Documented Applications
Therapeutic use against inflammatory/autoimmune indications and stress/apoptosis-related therapeutic indications, including interference with cytokine secretion such as TNF-α and IL-6 and anti-apoptotic effects.
Use of a pharmaceutical composition comprising the isolated peptide and a physiologically acceptable carrier.
Interested in licensing this patent?